A pharmacokinetic-pharmacodynamic model for neuromuscular blocking agents to predict train-of-four twitches

被引:2
|
作者
Eleveld, DJ [1 ]
De Haes, A [1 ]
Proost, JH [1 ]
Wierda, JMKH [1 ]
机构
[1] Res Grp Expt Anesthesiol & Clin Pharmacol, NL-9700 RB Groningen, Netherlands
关键词
neuromuscular relaxants; pharmacokinetics; models; computers; train-of-four stimulation;
D O I
10.1023/A:1024430413262
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The train-of-four (TOF) stimulation pattern consists of 4 stimuli (T1, T2, T3, and T4) at 2 Hz, and is used in daily anesthesiological practice to determine the degree of relaxation caused by muscle relaxants. At a surgical levels of relaxation the degree of relaxation can be estimated by counting the number of "measurable'' or "visible'' muscular reactions to the 4 stimuli in the TOF stimulation pattern (TOF count). During recovery relaxation can be estimated by calculating the TOF ratio (T4/T1). Bartkowski and Epstein described a pharmacokinetic-pharmacodynamic (PK-PD) model to predict TOF ratio by modifying and extending the PK-PD model as described by Sheiner to use a hypothetical distributed effect compartment described by a median equilibration rate constant and a dispersion parameter. We extended the Bartkowski and Epstein PK-PD model to simulate all four TOF twitches by including EC50 terms for T2 and T3. We fit this model to data from the pig and compared the results to fitted models using separate PD models for each TOF twitch ( extended Sheiner model). The extended Bartkowski and Epstein model fit the twitch height data from all four TOF twitches better than the extended Sheiner model and has fewer parameters.
引用
收藏
页码:105 / 118
页数:14
相关论文
共 50 条
  • [31] How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study
    Cessot, Anatole
    Narjoz, Celine
    Thomas-Schoemann, Audrey
    Boudou-Rouquette, Pascaline
    Golmard, Jean-Louis
    Durand, Jean-Philippe
    Emile, George
    Tod, Michel
    Vidal, Michel
    Loriot, Marie-Anne
    Blanchet, Benoit
    Goldwasser, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance
    Boissel, JP
    Nony, P
    CLINICAL PHARMACOKINETICS, 2002, 41 (01) : 1 - 6
  • [33] Using Pharmacokinetic-Pharmacodynamic Relationships to Predict the Effect of Poor Compliance
    Jean-Pierre Boissel
    Patrice Nony
    Clinical Pharmacokinetics, 2002, 41 : 1 - 6
  • [34] AN ANALYTICAL PHARMACODYNAMIC MODEL FOR NON-DEPOLARIZING NEUROMUSCULAR BLOCKING-AGENTS
    DHOLLANDER, A
    DELCROIX, C
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (01): : 27 - 40
  • [35] Accuracy and Precision of Three Acceleromyographs, Three Electromyographs, and a Mechanomyograph Measuring the Train-of-four Ratio in the Absence of Neuromuscular Blocking Drugs
    Wedemeyer, Zain
    Michaelsen, Kelly E.
    Jelacic, Srdjan
    Silliman, Willis
    Lopez, Aidan
    Togashi, Kei
    Bowdle, Andrew
    ANESTHESIOLOGY, 2024, 141 (02) : 262 - 271
  • [36] An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor
    Kamei, Hiroko
    Jackson, Robert C.
    Zheleva, Daniella
    Davidson, Fordyce A.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2010, 37 (04) : 407 - 434
  • [37] A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide
    Phillips, L
    Grasela, TH
    Agnew, JR
    Ludwig, EA
    Thompson, GA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 370 - 383
  • [38] A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy
    Ferrari, Myriam
    Bosa, Luigi
    De-Luca, Riccardo
    Barolo, Massimiliano
    Zambon, Carlo F.
    Pengo, Vittorio
    Padrini, Roberto
    Bezzo, Fabrizio
    26TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING (ESCAPE), PT B, 2016, 38B : 2313 - 2318
  • [39] Does Train-of-Four monitoring reduce recovery time after neuromuscular blockade?
    de Lemos, J
    Ronco, J
    CRITICAL CARE MEDICINE, 1998, 26 (11) : 1920 - 1920
  • [40] Development of a pharmacokinetic-pharmacodynamic model of inolimomab in GVHD patients
    Girard, P.
    Dartois, C.
    Michallet, M.
    Henin, E.
    Vermot-Desroches, C.
    Tranchand, B.
    Trillet-Lenoir, V
    Freyer, G.
    BULLETIN DU CANCER, 2008, 95 : S74 - S74